Within WFI loops, the potential for biofilm development is a critical threat that is primarily caused by laminar flow and the presence of dead zones in the pipework. Bürkert’s business development manager for pharma & biotech, Damien Moran, explains.
Shift Bioscience, a biotechnology company uncovering the biology of cell rejuvenation to develop new therapies for age driven diseases, has announced the publication of new research identifying a novel, single-gene target for cellular rejuvenation.
Thermo Fisher Scientific has announced the launch of the Thermo Scientific Orbitrap Astral Zoom mass spectrometer (MS) and the Thermo Scientific Orbitrap Excedion Pro mass spectrometer (MS) to help push the boundaries of scientific discovery.
A large-scale international study involving researchers from the Drug Safety Research Unit (DSRU), UK, highlights the relationship between SARS-CoV-2 infection, certain COVID-19 vaccines, and Guillain-Barré syndrome (GBS).
Osivax has announced that all participants have completed their final visit in the Phase 2a clinical booster trial (NCT06582277) evaluating OVX836, Osivax’ broad-spectrum influenza A vaccine candidate.
Just when pharmaceutical supply chains had begun to recover from the chaos of the pandemic, companies are now faced with the threat of US tariffs and the ongoing investigation into the United States’ reliance on drug imports.
Brenntag has announced the acquisition of mcePharma. The acquisition and additional investments in the site of mcePharma will "strengthen" Brenntag’s capabilities across the pharma and biopharma value chain.
Medicines Discovery Catapult (MDC) and the Francis Crick Institute have announced a new strategic partnership to support the delivery of KQ Labs, a national accelerator for data-driven health science start-ups.
European Pharmaceutical Manufacturer asks John McDermott, vice president of scientific consulting at Quotient Sciences what the benefits are of using a CRDMO?
OneChain Immunotherapeutics (OCI), a clinical-stage biotech company focused on the development of CAR-T therapies for the treatment of oncologic diseases, has announced the appointment of Barbara Krebs-Pohl as the new chair of the Board of Directors.
Enterome SA presented new positive data from its ongoing Phase 1/2 “AUDREY” trial of its OncoMimics immunotherapy, EO4010, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
